Figure 4

In vivo imaging of the surgical sites. (A) Anterior segment optical coherence tomography imaging of the mouse conjunctiva. The unoperated and operated eyes on days 2, 7, I4 and 28 were examined. The location of the bleb is indicated by the white box. Images shown belong to the same control or MMC-treated eye over the time course of the analysis. Ten control eyes and eight MMC-treated eyes were examined. C indicates cornea. (B) In vivo confocal microscopy images of the blebs. (i, v) The subconjunctival matrix of the unoperated eye is indicated by a white *. Numerous microcysts in the conjunctival matrix can be observed in both control (ii) and MMC-treated (vi) eyes 2 d after surgery. While the dull microdots in the control eye are likely to be inflammatory cells derived from the surrounding vascular or lymphatic network (iii), MMC treatment is associated with the presence of hyperreflective microdots, which may represent necrotic epithelial cells (vii). (iv) By day 28 in the control eye shown, the operated site appeared scar-like with a dense connective tissue with few or no clear spaces (black *). (viii) The MMC-treated operated site maintained numerous microcysts although some encapsulation may be present at the periphery of the bleb. Two eyes from each group were examined. CE, conjunctival epithelium; S, sclera.